The full content of Annals is available to subscribers

Subscribe/Learn More  >
Original Research |

Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report

Jameela Al-Salman, MD; Heider Arjomand, MD; David G. Kemp, MD; and Manoj Mittal, MD
[+] Article, Author, and Disclosure Information

From Easton Hospital, MCP-Hahnemann University, Easton, Pennsylvania.

Requests for Reprints: Manoj K. Mittal, MD, Division of Gastroenterology, Easton Hospital, 250 South 21st Street, Easton, PA 18042. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints@mail.acponline.org.

Current Author Addresses: Drs. Al-Salman, Arjomand, and Kemp: Department of Medicine, Easton Hospital, 250 South 21st Street, Easton, PA 18042.

Dr. Mittal: Division of Gastroenterology, Easton Hospital, 250 South 21st Street, Easton, PA 18042.

Author Contributions: Conception and design: J. Al-Salman, H. Arjomand.

Analysis and interpretation of data: J. Al-Salman, H. Arjomand, D.G. Kemp.

Drafting of the article: J. Al-Salman, H. Arjomand.

Critical revision of the article for important intellectual content: J. Al-Salman, H. Arjomand, D.G. Kemp.

Final approval of the article: J. Al-Salman, H. Arjomand, D.G. Kemp, M.K. Mittal.

Provision of study materials or patients: D.G. Kemp.

Administrative, technical, or logistic support: D.G. Kemp.

Collection and assembly of data: J. Al-Salman, H. Arjomand, D.G. Kemp.

Ann Intern Med. 2000;132(2):121-124. doi:10.7326/0003-4819-132-2-200001180-00006
Text Size: A A A

Background: Rosiglitazone maleate (Avandia, SmithKline Beecham, Philadelphia, Pennsylvania) is a new oral hypoglycemic agent approved for the treatment of type 2 diabetes. It acts primarily by increasing insulin sensitivity. In controlled trials, there has been no evidence of rosiglitazone-induced hepatocellular injury.

Objective: To report a case of hepatocellular injury in a patient receiving rosiglitazone.

Design: Case report.

Setting: Community teaching hospital.

Patient: 61-year-old man receiving rosiglitazone, 4 mg/d for 2 weeks.

Intervention: Discontinuation of rosiglitazone therapy.

Measurements: Clinical evaluation and assessment of liver function test results were done daily during hospitalization and periodically after discharge. The outpatient record was also reviewed.

Results: After receiving rosiglitazone for 2 weeks, the patient presented with anorexia, vomiting, and abdominal pain. Liver function tests revealed severe hepatocellular injury. Discontinuation of rosiglitazone therapy led to rapid improvement of liver function and resolution of symptoms.

Conclusion: Rosiglitazone may be associated with hepatocellular injury. We believe that patients receiving rosiglitazone should have liver enzyme levels monitored earlier and more frequently than initially recommended.


Grahic Jump Location
Alanine aminotransferase levels over time.

The patient was hospitalized 25 June 1999 through 2 July 1999. To convert U/L to nkat/L, multiply by 16.667.

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Liver Injury in a Person Taking the Diabetes Drug Rosiglitazone

The summary below is from the full report titled “Hepatocellular Injury in a Patient Receiving Rosiglitazone. A Case Report” It is in the 18 January 1999 issue of Annals of Internal Medicine (volume 131, pages 121-124). The authors are J. Al-Salman, H. Arjomand, D.G. Kemp, and M. Mittal.


Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.